Module

Progress of Entry Inhibitors: Where Are We Now and Where Are We Going?

Source: HIV/AIDS Annual Update 2006

Progress of Entry Inhibitors: Where Are We Now and Where Are We Going?

CME Program Director: John P. Phair, MD

Faculty:
Daniel R. Kuritzkes, MD

CME CREDIT INFORMATION

Release Date: 06/30/06

Expiration Date: 06/29/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss advantages and disadvantages of entry inhibition as a strategy for control of HIV-1 replication
Describe CXCR4-CCR5 coreceptor tropism switching and implications for disease progression
List results of phase II/III trials of CCR5 inhibitors in HIV-infected patients

Topics covered include:

Introduction
Overview of HIV-1 Entry
Inhibitors of HIV-1 Entry
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.